Aarey Drugs And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 35.50 Cr
- Paid Up Capital ₹ 28.45 Cr
- Company Age 34 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 64.44 Cr
- Satisfied Charges ₹ 38.84 Cr
- Revenue Growth -4.53%
- Profit Growth 24.20%
- Ebitda -16.06%
- Net Worth 13.07%
- Total Assets 4.11%
About Aarey Drugs And Pharmaceuticals
Aarey Drugs And Pharmaceuticals Limited (ADAPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 15 May 1990 and has a history of 34 years and nine months. Its registered office is in Thane, Maharashtra, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524412 and on the National Stock Exchange(NSE) under AAREYDRUGS.
The Corporate was formerly known as Niharika Textiles And Chemicals Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 35.50 Cr and a paid-up capital of Rs 28.45 Cr.
The company currently has active open charges totaling ₹64.44 Cr. The company has closed loans amounting to ₹38.84 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Aarey Drugs And Pharmaceuticals Limited India is Mira Ghatalia as CFO. Mihir Ghatalia, Bina Ghatalia, Chetan Mehta, and Three other members serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
L99999MH1990PLC056538
- Company No.
056538
- Stock Symbol
BSE : 524412 NSE : AAREYDRUGS
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
15 May 1990
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Listed
- ROC Code
Roc Mumbai
Industry
What products or services does Aarey Drugs And Pharmaceuticals Limited offer?
Aarey Drugs And Pharmaceuticals Limited offers a wide range of products and services, including Organic and Inorganic Solvents, Alcohol Solvents, Industrial Chemicals & Supplies, Agro Chemicals, Chlorinated Solvents, Organic Chemicals, N-Propyl Acetate, Chemical Intermediates, Acetic Acid, Diacetone Alcohol.
Who are the key members and board of directors at Aarey Drugs And Pharmaceuticals?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mihir Ghatalia  | Managing Director | 02-Aug-2004 | Current |
| Mira Ghatalia | CFO | 04-Jan-2021 | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nimit Ghatalia | Director | 01-Jul-2020 | Current |
| Chetan Mehta | Director | 02-Jun-2008 | Current |
| Bina Ghatalia | Director | 09-Oct-2023 | Current |
| Lalit Tulsiani | Director | 29-Jan-2020 | Current |
| Anil Mandal | Director | 01-Jul-2020 | Current |
Financial Performance of Aarey Drugs And Pharmaceuticals.
Aarey Drugs And Pharmaceuticals Limited, for the financial year ended 2024, experienced Minor drop in revenue, with a 4.53% decrease. The company also saw a substantial improvement in profitability, with a 24.2% increase in profit. The company's net worth Soared by an impressive increase of 13.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aarey Drugs And Pharmaceuticals?
In 2023, Aarey Drugs And Pharmaceuticals had a promoter holding of 50.05% and a public holding of 49.95%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Worth Investment & Trading Co LtdMihir Ghatalia, Lalit Tulsiani and 2 more are mutual person
Enam Organics India LimitedMihir Ghatalia, Nimit Ghatalia and 1 more are mutual person
- Aarey Pharma Park Private Limited
Mihir Ghatalia and Nimit Ghatalia are mutual person
- Designs By The Bay Llp
Nimit Ghatalia is a mutual person
- Nimit Impex Private Limited
Nimit Ghatalia is a mutual person
- Suraj Tradelinks Private Limited
Nimit Ghatalia is a mutual person
Charges (Loans)
₹64.44 Cr
₹38.84 Cr
Charges Breakdown by Lending Institutions
- State Bank Of India : 64.44 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Jan 2023 | State Bank Of India | ₹64.44 Cr | Open |
| 19 Dec 2022 | Others | ₹1.67 Cr | Satisfied |
| 12 Sep 2022 | Others | ₹4.00 Cr | Satisfied |
| 07 Sep 2021 | Others | ₹3.34 Cr | Satisfied |
| 23 Apr 2020 | Others | ₹1.95 Cr | Satisfied |
How Many Employees Work at Aarey Drugs And Pharmaceuticals?
Unlock and access historical data on people associated with Aarey Drugs And Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aarey Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aarey Drugs And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
